<DOC>
	<DOCNO>NCT02534350</DOCNO>
	<brief_summary>This study evaluate effect presatovir nasal respiratory syncytial virus ( RSV ) viral load RSV-positive lung transplant ( LT ) recipients acute respiratory symptom .</brief_summary>
	<brief_title>Presatovir Lung Transplant ( LT ) Recipients With Respiratory Syncytial Virus ( RSV ) Infection</brief_title>
	<detailed_description />
	<criteria>Key Received LT ( single double ) heart/lung transplant &gt; 90 day prior screen Confirmed RSVpositive local polymerase chain reaction ( PCR ) testing ( start upper low respiratory tract sample obtain ) ≤ 7 day prior study drug administration Day 1/baseline New onset acute worsen least 1 follow respiratory symptom ≤ 7 day prior study drug administration : nasal congestion , earache , runny nose , cough , sore throat , shortness breath , wheeze An informed consent document sign date individual A negative urine serum pregnancy test female childbearing potential Agreement male females childbearing potential use contraception Ability willingness complete necessary study procedure Key Related concomitant previous medication use : Use follow lympholytic treatment : antithymocyte globulin ( ATG ) , &lt; 3 month ; antilymphoblast globulin ( ALG ) , &lt; 3 month ; muromonabCD3 ( OKT3 ) , &lt; 3 month ; rituximab &lt; 6 month ; alemtuzumab &lt; 9 month Related transplant history : Recipient organ transplant prior screening , exception LT ( single double ) heart/lung transplant Recipient hematopoietic cell transplant time Presence BOS Stage 3 screening define FEV1 50 % less baseline Related medical condition screening : Respiratory failure require invasive mechanical ventilation Evidence shock require vasopressor Known viral coinfection ( include limit influenza , metapneumovirus , human rhinovirus , parainfluenza , cytomegalovirus , coronavirus ) upper low respiratory tract ≤ 14 day prior screen unless discuss medical monitor deem acceptable Active systemic infection infectious pneumonia etiology ( ie , bacterial , viral [ RSV ] fungal ) , include aspiration pneumonia , consider clinically significant investigator unless discuss medical monitor deem acceptable Pregnant lactating female Evidence recent rapidly deteriorate lung function , occur onset current viral respiratory infection Related allergy : Known hypersensitivity allergy study drug , metabolite , formulation excipients ( microcrystalline cellulose , mannitol , croscarmellose sodium , magnesium stearate , polyvinyl alcohol , titanium dioxide , polyethylene glycol talc ) History hypersensitivity , anaphylactic reaction , StevensJohnson Syndrome , toxic epidermal necrolysis response sulfa drug Related laboratory value : Clinically significant kidney dysfunction Clinically significant liver function test abnormality Clinically significant elevation total bilirubin ( TB ) , determine investigator NOTE : Other protocol define Inclusion/ Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Respiratory Syncytial Virus ( RSV )</keyword>
	<keyword>Antiviral</keyword>
	<keyword>Lung Transplant</keyword>
</DOC>